Eli Lilly and Company (LLY) faces challenges with a recent “mini-tender” offer and a 3.2% drop in share price. Stock AI predicts a short-term decrease of 3.0% but a long-term increase of 1.2%. 🟢🔴
Stock AI’s (LLY) Forecast get (+6.5% Profit)
StockAI’s analysis delivers real-world results. On 11 April 2024, $LLY ($753.8), StockAI predicted a long-term 🟢 buy signal. It was accurate: 1 month later price increased to $803.1 (🟢6.5%). Buying LLY on this signal yielded a +6.5% profit 💰💰.
LLY-Eli Lilly and Company News
🔴 Eli Lilly and Company reached a settlement agreement with a medi spa that sold counterfeit versions of its popular diabetes drug.
🟢 Eli Lilly and Company announced a quarterly dividend of $1.30 per share, representing a $5.20 annual dividend.
🔴 Eli Lilly and Company notified shareholders to reject an unsolicited “mini-tender” offer by Tutanota LLC.
🟢 Cannell & Co. increased its stake in Eli Lilly and Company by 65.9% in the fourth quarter.
🔴 International Assets Investment Management LLC raised its position in shares of Eli Lilly and Company by 5.3% in the fourth quarter.
🟢 Argus raised their price target on Eli Lilly and Company from $770.00 to $840.00, with a buy rating on the stock.
Recent news for Eli Lilly and Company stock has been a mix of positive and negative developments. The settlement agreement with the medi spa is a negative impact, while the announcement of a quarterly dividend and the increase in stake by Cannell & Co. and International Assets Investment Management LLC are positive factors. The recommendation to reject the “mini-tender” offer and the price target raise by Argus also have conflicting impacts on the stock price.
Overall, despite the mixed news, the positive developments such as the dividend announcement and stake increases may have a more significant impact on the stock price in the long term. Investors should keep an eye on how these factors play out in the market and adjust their strategies accordingly.
LLY-Eli Lilly and Company Analyst Ratings
📉 BMO Capital Markets raised their price target on Eli Lilly and Company stock from $900.00 to $1,001.00 in a recent report.
📈 JPMorgan Chase & Co. upgraded Eli Lilly and Company stock from $850.00 to $900.00 in a report published on Wednesday.
📈 Argus raised their price target on Eli Lilly and Company stock from $770.00 to $840.00 after a recent analysis.
Sources:
– ETF Daily News
– ETF Daily News
– ETF Daily News
Disclaimer
Investors may consider the AI predictions and news summaries as one factor in their investment decisions alongside their own research and risk tolerance.
Ready to analyze your own portfolio?
Get the same AI-powered insights for any stock you choose. It's easy!
